Alfanotide can treat vitiligo, but the effect of treatment varies from person to person. It should be treated according to the actual situation of the patient to avoid blindly using drugs. Vitiligo is a refractory depigmented skin disease, seriously affecting the patient’s quality of life, often associated with a variety of other autoimmune diseases, the current treatment is mainly topical corticosteroids, narrow-spectrum medium-wave ultraviolet (UVB) based. Alfanotide is an α-MSH analog that stimulates melanin synthesis and melanocyte proliferation, providing photoprotection to the skin. Some studies have shown that the combination of narrow-spectrum medium-wave ultraviolet (UVB) light and alfanotide has a higher rate of recoloration. It is important to note that sun protection and light avoidance measures are maintained during treatment with this product and that there is little experience with the use of this medication, which should be used under medical supervision. CAUTION: May result in increased skin pigmentation and darkening of pre-existing moles and freckles, a comprehensive skin examination is recommended 2 times per year to monitor existing and new skin pigmentation lesions. For vitiligo patients, Alfanotide should not be used without authorization and should be used under professional medical supervision. In case of discomfort, seek medical advice promptly.